Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964055 | 0.90 | CYP3A4 (0.79) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL14087054 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6285045 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6278227 | 0.89 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6277791 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6282564 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL5226211 | 0.83 | CYP3A4 (0.91) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6285119 | 0.81 | CYP3A4 (0.84) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL13647544 | 0.79 | CYP3A4 (0.53) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL4033917 | 0.79 | CYP3A4 (0.84) | CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070927-A1 | Substituted Heterocyclic Compounds | ZABLOCKI JEFF | 2008-03-20 | — | — | US | claimed |
| US-7271169-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | claimed |
| EP-1789407-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | claimed |
| WO-2006029179-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20060052605-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | claimed |
| US-7601721-B2 | Substituted heterocyclic compounds | GILEAD PALO ALTO, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601721-B2 | Substituted heterocyclic compounds | GILEAD PALO ALTO, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601721-B2 | Substituted heterocyclic compounds | GILEAD PALO ALTO, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | ZABLOCKI JEFF | 2008-03-20 | — | — | US | disclosed |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | ZABLOCKI JEFF | 2008-03-20 | — | — | US | disclosed |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | ZABLOCKI JEFF | 2008-03-20 | — | — | US | disclosed |
| US-7271169-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271169-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271169-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1789407-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029179-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006029179-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052605-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052605-A1 | Substituted heterocyclic compounds | KCNH1, KCNJ2, KCNJ1 | CYP3A4 1120/4885CYP1A2 1121/4885CYP2C9 1149/4885 |
| US-20080070927-A1 | Substituted Heterocyclic Compounds | KCNJ2, KCNH1, KCNJ1 | CYP3A4 1454/4885CYP1A2 1155/4885CYP2C9 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.